Search bioRxiv⌕ Search

Biology subjects

Raverdy, V.

Publications and source records attributed to Raverdy, V..

2 recordsLinked to original sources

Deep learning models reading clinical data and liver omics strongly distinguish NASH from steatosis and suggest new genes involved in liver disease severity

Background & AimsMetabolic dysfunction-associated steatotic liver disease (MASLD, previously NAFLD) is a frequent co-morbidity of obesity and diabetes, with prevalence increasing worldwide in all age groups and both sexes. Only early stages of the disease are fully reversible. Recognising liver disease stages and elucidating the molecular underpinning of their progression are thus medically important. We developed a deep learning model to recognise simple steatosis from steatohepatitis combining liver transcriptomics, epigenetics, and clinical data. MethodsWe used clinical data, liver gene expression and liver DNA methylation gathered from 300 patients with obesity of the ABOS cohort (80 without NAFLD, 137 with simple steatosis, 83 with steatohepatitis). We selected non-redundant clinical variables, gene expressions and CpGs methylation levels most associated with severity using unsupervised approaches. We designed a multi-module, multi-layer perceptron to predict patients liver status. We trained five model instances on independent training/test sets and combined the predictions. ResultsWe used a score based on gene expression/DNA methylation and relevant principal component analysis (PCA) loadings to select 200 genes and 260 CpG methylations. Models trained on the three modalities reached an AUC of 0.945 overall on a validation set with accuracies above 81% for simple steatosis and 88% for NASH, outperforming any other machine learning model so far. We retrieved patient clusters previously found using clinical variables in the latent space of our clinical data module, but not in the gene expression and DNA methylation modules. While all three modules are needed to reach the best prediction accuracy in all classes, the gene expression module had the most impact on the decision. Independent models weighted gene expression inputs similarly, shining light on their importance. The most impactful genes were linked to immune responses and extracellular matrix. However, many of those genes were previously unassociated with steatotic liver disease onset or progression. ConclusionsA multi-omics deep-learning model can recognise steatohepatitis from simple liver steatosis with an AUC of 0.945 and identify new genes potentially involved in NAFLD progression. Gene expressions profiles predicting disease severity are largely different from those specific of clinical variable clusters. Impact and implicationsThis study suggests that clinical variables are not sufficient to recognise the severity of steatotic liver disease with high accuracy, but model efficiency increases when used together with liver epigenetics and transcriptomics.

molecular biology↗

The Circadian Clock Controls Hepatic Stellate Cell Activation in Liver Fibrosis via a BMAL1/CK1ϵ/REV-ERBα/Transgelin Signaling Pathway.

Liver fibrosis is a progressive and life-threatening condition with no effective targeted treatments. Growing evidence indicates a two-way relationship between circadian rhythm and fibrogenesis, although the specific molecular signaling pathways involved are still not well understood. The molecular clock, which governs circadian rhythms, regulates metabolic and cellular functions, and its pharmacological manipulation has shown potential as a therapy for organ fibrosis. Although the livers molecular clock appeared resilient to the progression of chronic liver disease in humans from steatosis to fibrosis, detectable changes in the daily amplitude of clock genes were observed in a cohort of people living with obesity. We discovered a clock-controlled signaling pathway that drives hepatic stellate cell (HSC) activation, a key event in fibrosis progression. Interfering with this pathway, either by disrupting the core regulator CLOCK:BMAL1 or activating the nuclear receptors REV-ERBs, significantly reduced HSC activation. We also identified transgelin as the downstream effector of clock-regulated HSC contractility, a characteristic of HSC activation. Transgelin is regulated indirectly by a BMAL1-CK1{varepsilon} signaling pathway and directly by REV-ERB. Our findings identify a previously unknown circadian-controlled mechanism that links the molecular clock to HSC activation and cell contractile function, which is relevant to human diseases. This pathway provides several entry points for drugs to target and disrupt fibrogenic signaling. By connecting clock biology to the cellular processes that cause fibrosis, our work also offers a mechanistic basis for chronotherapeutic strategies against chronic liver disease.

molecular biology↗